Download

Full Text

• Bataille, S., Serveaux, M., Carreno, E., Pedinielli, N., Darmon, P., Robert, A., The diagnosis of sarcopenia is mainly driven by muscle mass in hemodialysis patients. Clin Nutr 36 (2017), 1654–1660.
• Kopple, J.D., Kim, J.C., Shapiro, B.B., et al. Factors affecting daily physical activity and physical performance in maintenance dialysis patients. J Ren Nutr 25 (2015), 217–222.
• Kittiskulnam, P., Chertow, G.M., Carrero, J.J., Delgado, C., Kaysen, G.A., Johansen, K.L., Sarcopenia and its individual criteria are associated, in part, with mortality among patients on hemodialysis. Kidney Int 92 (2017), 238–247.
• Vogt, B.P., Borges, M.C., Goés, C.R., Caramori, J.C., Handgrip strength is an independent predictor of all-cause mortality in maintenance dialysis patients. Clin Nutr 35 (2016), 1429–1433.
• Carrero, J.J., Johansen, K.L., Lindholm, B., Stenvinkel, P., Cuppari, L., Avesani, C.M., Screening for muscle wasting and dysfunction in patients with chronic kidney disease. Kidney Int 90 (2016), 53–66.
• Manfredini, F., Mallamaci, F., D'Arrigo, G., et al. Exercise in patients on dialysis: a Multicenter, Randomized clinical trial. J Am Soc Nephrol 28 (2017), 1259–1268.
• Moreau-Gaudry, X., Guebre-Egziabher, F., Jean, G., et al. Serum creatinine improves body mass index survival prediction in hemodialysis patients: a 1-year prospective cohort analysis from the ARNOS study. J Ren Nutr 21 (2011), 369–375.
• Cavalier, E., Beaudart, C., Buckinx, F., Bruyère, O., Reginster, J.Y., Critical analytical evaluation of promising markers for sarcopenia. Eur Geriatr Med 7 (2016), 239–242.
• Jia, T., Axelsson, T.G., Heimbürger, O., et al. IGF-1 and survival in ESRD. Clin J Am Soc Nephrol 9 (2014), 120–127.
• Sun, D.F., Chen, Y., Rabkin, R., Work-induced changes in skeletal muscle IGF-1 and myostatin gene expression in uremia. Kidney Int 70 (2006), 453–459.
• Loumaye, A., De Barsy, M., Nachit, M., et al. Role of activin A and myostatin in human cancer cachexia. J Clin Endocrinol Metab 100 (2015), 2030–2038.
• Buehring, B., Binkley, N., Myostatin - the holy grail for muscle, bone, and fat?. Curr Osteoporos Rep 11 (2013), 407–414.
• White, T.A., Lebrasseur, N.K., Myostatin and sarcopenia: Opportunities and challenges - a mini-review. Gerontology 60 (2014), 289–293.
• Miyamoto, T., Carrero, J.J., Qureshi, A.R., et al. Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survival. Clin J Am Soc Nephrol 6 (2011), 1001–1008.
• Berry, S.D., Ramachandran, V.S., Cawthon, P.M., et al. Procollagen type III N-terminal peptide (P3NP) and lean mass: a cross-sectional study. J Frailty Aging 2 (2013), 129–134.
• Cavalier, E., Delanaye, P., Vranken, L., et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transpl 27 (2012), 1950–1956.
• Delanaye, P., Quinonez, K., Buckinx, F., Krzesinski, J.-M., Bruyère, O., Hand grip strength measurement in haemodialysis patients: before or after the session?. Clin Kidney J, 2018, 1–4.
• Roberts, H.C., Denison, H.J., Martin, H.J., et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing 40 (2011), 423–429.
• Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working Group on sarcopenia in older People. Age Ageing 39 (2010), 412–423.
• Rymarz, A., Bartoszewicz, Z., Szamotulska, K., Niemczyk, S., The associations between body cell mass and nutritional and inflammatory markers in patients with chronic kidney disease and in subjects without kidney disease. J Ren Nutr 26 (2016), 87–92.
• Han, D.S., Chen, Y.M., Lin, S.Y., et al. Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis. Clin Endocrinol (Oxf) 75 (2011), 857–863.
• Qureshi, A.R., Alvestrand, A., Danielsson, A., et al. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int 53 (1998), 773–782.
• Besbas, N., Ozaltin, F., Coşkun, T., et al. Relationship of leptin and insulin-like growth factor I to nutritional status in hemodialyzed children. Pediatr Nephrol 18 (2003), 1255–1259.
• Jacob, V., Le Carpentier, J.E., Salzano, S., et al. IGF-I, a marker of undernutrition in hemodialysis patients. Am J Clin Nutr 52 (1990), 39–44.
• Zhang, L., Wang, X.H., Wang, H., Du, J., Mitch, W.E., Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J Am Soc Nephrol 21 (2010), 419–427.
• da Costa, J.A.C., Ikizler, T.A., Inflammation and insulin resistance as novel mechanisms of wasting in chronic dialysis patients. Semin Dial 22 (2009), 652–657.
• Trendelenburg, A.U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., Glass, D.J., Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 296 (2009), C1258–C1270.
• Cheung, W.W., Rosengren, S., Boyle, D.L., Mak, R.H., Modulation of melanocortin signaling ameliorates uremic cachexia. Kidney Int 74 (2008), 180–186.
• Schuelke, M., Wagner, K.R., Stolz, L.E., et al. Myostatin mutation associated with Gross muscle Hypertrophy in a Child. N Engl J Med 351 (2004), 2682–2688.
• Breitbart, A., Scharf, G.M., Duncker, D., et al. Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients. PLoS One, 8, 2013, e80454.
• Ju, C.R., Chen, R.C., Serum myostatin levels and skeletal muscle wasting in chronic obstructive pulmonary disease. Respir Med 106 (2012), 102–108.
• Yarasheski, K.E., Bhasin, S., Sinha-Hikim, I., Pak-Loduca, J., Gonzalez-Cadavid, N.F., Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting. J Nutr Health Aging 6 (2002), 343–348.
• Han, D.S., Hsiao, M.Y., Wang, T.G., Chen, S.Y., Yang, W.S., Association of serum myokines and aerobic exercise training in patients with spinal cord injury: an observational study. BMC Neurol, 16, 2016, 142.
• Szulc, P., Schoppet, M., Goettsch, C., et al. Endocrine and clinical correlates of myostatin serum concentration in men - the STRAMBO study. J Clin Endocrinol Metab 97 (2012), 3700–3708.
• Ma, Y., Li, X., Zhang, H., et al. Serum myostatin in central south Chinese postmenopausal women: relationship with body composition, lipids and bone mineral density. Endocr Res 41 (2016), 223–228.
• Lakshman, K.M., Bhasin, S., Corcoran, C., et al. Measurement of myostatin concentrations in human serum: Circulating concentrations in young and older men and effects of testosterone administration. Mol Cell Endocrinol 302 (2009), 26–32.
• Zachwieja, J.J., Smith, S.R., Sinha-Hikim, I., Gonzalez-Cadavid, N., Bhasin, S., Plasma myostatin-immunoreactive protein is increased after prolonged bed rest with low-dose T3 administration. J Gravit Physiol 6 (1999), 11–15.
• Buehring, B., Siglinsky, E., Krueger, D., et al. Comparison of muscle/lean mass measurement methods: correlation with functional and biochemical testing. Osteoporos Int 29 (2018), 675–683.
• Burch, P.M., Pogoryelova, O., Palandra, J., et al. Reduced serum myostatin concentrations associated with genetic muscle disease progression. J Neurol 264 (2017), 541–553.
• Bergen, H.R., Farr, J.N., Vanderboom, P.M., et al. Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: Insights using a new mass spectrometry-based assay. Skelet Muscle, 5, 2015, 21.
• Yamada, S., Tsuruya, K., Yoshida, H., et al. Factors associated with the serum myostatin Level in patients Undergoing peritoneal dialysis: potential effects of skeletal muscle mass and Vitamin D receptor activator Use. Calcif Tissue Int 99 (2016), 13–22.
• Anaya-Segura, M.A., García-Martínez, F.A., Montes-Almanza, L.Á., et al. Non-Invasive biomarkers for duchenne muscular dystrophy and Carrier detection. Molecules 20 (2015), 11154–11172.
• Han, D.S., Yu, C.S., Chiang, C.K., et al. Serum myostatin is reduced in individuals with metabolic syndrome. PLoS One, 9, 2014.
• Carrero, J.J., Qureshi, A.R., Nakashima, A., et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transpl 26 (2011), 184–190.
• Carrero, J.J., Chmielewski, M., Axelsson, J., et al. Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. Clin Nutr 27 (2008), 557–564.
• Enoki, Y., Watanabe, H., Arake, R., et al. Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1. Sci Rep, 6, 2016, 32084.
• Avin, K.G., Chen, N.X., Organ, J.M., et al. Skeletal muscle regeneration and oxidative stress are altered in chronic kidney disease. PLoS One 11 (2016), 1–15.
• Guernec, A., Chevalier, B., Duclos, M.J., Nutrient supply enhances both IGF-I and MSTN mRNA levels in chicken skeletal muscle. Domes Anim Endocrinol 26 (2004), 143–154.
• Zhang, L., Pan, J., Dong, Y., et al. Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab 18 (2013), 368–379.
• Saran, R., Goel, S., Stack, A., et al. Serum insulin-like growth factor I levels do not correlate with residual renal function in dialysis patients. Perit Dial Int 21 (2001), 522–525.
• Bohé, J., Joly, M.O., Arkouche, W., Laville, M., Fouque, D., Haemodialysis with the biocompatible high permeability AN-69 membrane does not alter plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3. Nephrol Dial Transpl 16 (2001), 590–594.
• Ma, K., Mallidis, C., Bhasin, S., et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 285 (2003), 363–371.
• Clemmons, D.R., Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 6 (2007), 821–833.